|
|
News Breaks | | | | December 4, 2012 | | 16:15 EDT |  | THRX | Theravance initiates Phase 2 study with TD-9855 for treatment of fibromyalgia
announced today initiation of a fibromyalgia Phase 2 study with TD-9855. TD-9855 is an investigational norepinephrine and serotonin reuptake inhibitor for the treatment of central nervous system conditions such as chronic pain and Attention-Deficit/Hyperactivity Disorder. | |
|
News For THRX From The Last 14 Days Check below for free stories on THRX the last two weeks. |
|
|
| June 17, 2013 | | 08:23 EDT | | THRX | Elan holders do not approve Theravance/Elan royalty participation transaction
 Subscribe for More Information | | | June 14, 2013 | | 05:35 EDT | | THRX | Elan holders vote against Theravance, AOP transactions
Royalty Pharma announces that holders of approximately 311M Elan (ELN) ADSs, representing more than 81% of the Elan ADSs held in street name, had voted on the Elan proposals through Broadridge. Based on a review of those votes, a sufficient number of these ADSs have been voted AGAINST both the Theravance (THRX) Transaction and the AOP Transaction such that Royalty Pharma is confident that those proposals will not pass at Elan's June 17 EGM. A narrow majority of these ADSs have been voted AGAINST the ELND005 Transaction. A narrow majority of these ADSs have been voted FOR the Share Repurchase Program but this majority can be overturned by a sufficient vote by ordinary shareholders. There can be no assurance that Elan will conduct a sale process, that any sale process that is conducted will be conducted fairly, or that any proposal to acquire Elan will be presented to Elan Shareholders. Even if Elan does conduct a sale process, given that Royalty Pharma's offer of $13 plus an up to $2.50 CVR has been deemed "grossly inadequate" by Elan, there can be no assurance that Elan will not conclude that all other offers they receive are "grossly inadequate". | | | June 10, 2013 | | 05:35 EDT | | THRX | Elan tells advisors to assess all strategic interests
Subscribe for More Information | | | June 7, 2013 | | 06:41 EDT | | THRX | Royalty Pharma raises offer for Elan to $13 per share plus CVR
Royalty Pharma announced that it increased its offer for Elan to $13.00 in cash per share plus a contingent value right worth up to $2.50 per share. The consideration is not conditional on due diligence, Royalty added. Royalty Pharma said it will waive down the acceptance yhreshold to 50% plus one share if all other conditions to its increased offer are satisfied, fulfilled or, to the extent permitted, waived. Royalty Pharma noted that its offer will lapse if the Theravance (THRX) resolution or any of the other resolutions are approved by Elan stockholders. | |
|
|
|
|
|
|
